SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

Launched by SUN YAT-SEN UNIVERSITY · Dec 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with unresectable hepatocellular carcinoma (HCC), which is a type of liver cancer that cannot be surgically removed. The trial will compare two treatment options: one group will receive a combination of SBRT (a type of targeted radiation therapy), Camrelizumab, and Apatinib, while another group will receive just Camrelizumab and Apatinib. The goal is to see which combination works better in helping patients whose cancer cannot be surgically operated on.

To participate in the trial, individuals need to be at least 18 years old and have a confirmed diagnosis of HCC. They should also have specific types of liver disease and a good performance status, meaning they can carry out daily activities with minimal assistance. Participants will need to sign a consent form to join the study, and they will be closely monitored throughout the trial for safety and effectiveness. This trial is currently not recruiting participants yet, but it aims to offer new hope for patients facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed Informed Consent Form (ICF).
• • Aged 18 years or older.
• • Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
• • Barcelona Clinic Liver Cancer stage B or C disease, which was not amenable to radical surgery.
• • ECOG Performance Status of 0 or 1.
• • Child-Pugh class of A.
• Exclusion Criteria:
• • Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously.
• • Existence of active autoimmune disease or history of autoimmune disease and may relapse.
• • Patients with innate or acquired immune deficiency (e.g., HIV infection).
• • Known allergies to study drugs or excipients.